O
Olivier Godeaux
Researcher at GlaxoSmithKline
Publications - 21
Citations - 1858
Olivier Godeaux is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Immunogenicity. The author has an hindex of 13, co-authored 19 publications receiving 1567 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal,Anthony L. Cunningham,Olivier Godeaux,Roman Chlibek,Javier Díez-Domingo,Shinn-Jang Hwang,Myron J. Levin,Janet E. McElhaney,Airi Poder,Joan Puig-Barberà,Timo Vesikari,Daisuke Watanabe,Lily Yin Weckx,Toufik Zahaf,Thomas C. Heineman +14 more
TL;DR: The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older and was similar to that in the other two age groups.
Journal ArticleDOI
A field trial to assess a blood-Stage malaria vaccine
Mahamadou A. Thera,Ogobara K. Doumbo,Drissa Coulibaly,Matthew B. Laurens,Amed Ouattara,Abdoulaye K. Kone,Ando B. Guindo,Karim Traore,Idrissa Traore,Bourema Kouriba,Dapa A. Diallo,Issa Diarra,Modibo Daou,Amagana Dolo,Youssouf Tolo,Mahamadou S. Sissoko,Amadou Niangaly,Mady Sissoko,Shannon Takala-Harrison,Kirsten E. Lyke,Yukun Wu,William C. Blackwelder,Olivier Godeaux,Johan Vekemans,Marie-Claude Dubois,W. Ripley Ballou,Joe Cohen,Darby J. S. Thompson,Tina J. T. Dube,Lorraine Soisson,Carter L. Diggs,Brent House,David E. Lanar,Sheetij Dutta,D. Gray Heppner,Christopher V. Plowe +35 more
TL;DR: The malaria vaccine did not provide significant protection against clinical malaria, but on the basis of secondary results, it may have strain-specific efficacy.
Journal ArticleDOI
Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
Tiina Petäjä,Heli Keränen,Tiina Karppa,Anna Kawa,Sirkku Lantela,Mari Siitari-Mattila,Helena Levänen,Tuomas Tocklin,Olivier Godeaux,Matti Lehtinen,Gary Dubin +10 more
TL;DR: The HPV-16/18 AS04-adjuvanted vaccine is immunogenic and well tolerated in boys aged 10 to 18 years, and further data on the potential public health benefits of vaccination of boys are required before any recommendations can be made.
Journal ArticleDOI
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
Anthony L. Cunningham,Thomas C. Heineman,Himal Lal,Olivier Godeaux,Roman Chlibek,Shinn-Jang Hwang,Janet E. McElhaney,Timo Vesikari,Charles P. Andrews,Won Suk Choi,Meral Esen,Hideyuki Ikematsu,Martina Kovac Choma,Karlis Pauksens,Stéphanie Ravault,Bruno Salaun,Tino F. Schwarz,Jan Smetana,Carline Vanden Abeele,Peter Van den Steen,Ilse Vastiau,Lily Yin Weckx,Myron J. Levin,Zoe +23 more
TL;DR: Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination, and the proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups.
Journal ArticleDOI
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson,George Risi,Matthew Davis,Eric Sheldon,Mira Baron,Ping Li,Miguel Madariaga,Louis Fries,Olivier Godeaux,David W. Vaughn +9 more
TL;DR: A single dose of the 3.75-μg HA AS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.